Ontology highlight
ABSTRACT:
SUBMITTER: Samara E
PROVIDER: S-EPMC4263161 | biostudies-other | 2014 Jan
REPOSITORIES: biostudies-other
Samara Emil E Winkle Peter P Pardo Patricia P Henney Herbert R HR Way Susan L SL Brown Eppie E Lee Angela A Blight Andrew R AR
Journal of clinical pharmacology 20131022 1
Dalfampridine extended release tablets (D-ER; prolonged-release fampridine in Europe) are available to improve walking in patients with multiple sclerosis (MS). D-ER is mainly renally eliminated; the approved 10-mg twice daily dose is contraindicated in the United States in patients with moderate or severe renal impairment. This study evaluated single-dose and steady-state pharmacokinetics of a 7.5-mg dose of D-ER in healthy subjects (n = 13) and subjects with mild (n = 17) and moderate (n = 12) ...[more]